Spinning a food-tech company out of a biotechnology platform

Situation

Synthetic Genomics held proprietary technology with significant promise as a food ingredient platform.

Challenge

The technology sat inside a biotech parent whose commercial focus lay elsewhere. The work required carving the IP out into a standalone company, capitalizing it, building an executive team from scratch, and proving commercial demand in parallel.

Actions

• →Built the value proposition, financial models, and CIM investor materials, then led the investor road show for strategic and private-equity audiences.
• →Recruited and hired the executive bench, including the Chief Science Officer and Chief Strategy Officer, and established a working cadence with the board and lead investment group.
• →Opened negotiations with a multinational food ingredient company for a global partnership while moving customer conversations toward signed terms.

Results

• →IP successfully spun out and capitalized as a standalone food technology company.
• →Term sheets executed with global customers across multiple revenue commitments.
• →Supply agreements secured during the Synthetic Genomics phase added another $27 million in revenue commitments.
• →Executive team and governance structure in place to scale.